The stock of Recro Pharma Inc (NASDAQ:REPH) is a huge mover today! About 238,951 shares traded hands. Recro Pharma Inc (NASDAQ:REPH) has risen 25.32% since April 27, 2016 and is uptrending. It has outperformed by 20.10% the S&P500.
The move comes after 7 months negative chart setup for the $90.85 million company. It was reported on Nov, 30 by Barchart.com. We have $7.57 PT which if reached, will make NASDAQ:REPH worth $4.54 million less.
Analysts await Recro Pharma Inc (NASDAQ:REPH) to report earnings on March, 23. They expect $-0.90 EPS, down 157.14% or $0.55 from last year’s $-0.35 per share. After $-0.50 actual EPS reported by Recro Pharma Inc for the previous quarter, Wall Street now forecasts 80.00% negative EPS growth.
Recro Pharma Inc (NASDAQ:REPH) Ratings Coverage
Out of 6 analysts covering Recro Pharma (NASDAQ:REPH), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Recro Pharma has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. H.C. Wainwright initiated it with “Buy” rating and $19 target price in Wednesday, September 2 report. H.C. Wainwright initiated Recro Pharma Inc (NASDAQ:REPH) rating on Tuesday, November 24. H.C. Wainwright has “Buy” rating and $14 price target. The stock has “Buy” rating given by Brean Capital on Monday, October 3. The firm has “Buy” rating given on Friday, September 16 by TH Capital. The rating was initiated by Janney Capital with “Buy” on Monday, August 29. On Monday, November 14 the stock rating was initiated by Aegis Capital with “Buy”. The stock has “Hold” rating given by Zacks on Tuesday, August 25. As per Friday, September 16, the company rating was initiated by Roth Capital.
According to Zacks Investment Research, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.”
Insitutional Activity: The institutional sentiment increased to 2.22 in 2016 Q2. Its up 0.42, from 1.8 in 2016Q1. The ratio increased, as 1 funds sold all Recro Pharma Inc shares owned while 4 reduced positions. 4 funds bought stakes while 5 increased positions. They now own 3.87 million shares or 0.55% less from 3.89 million shares in 2016Q1.
Globeflex L P owns 101 shares or 0% of their US portfolio. Blackrock Fund Advisors reported 15,268 shares or 0% of all its holdings. Retail Bank Of America De accumulated 0% or 55 shares. Blackrock Advsr Limited Liability reported 1,103 shares or 0% of all its holdings. Morgan Stanley, a New York-based fund reported 7,724 shares. Wells Fargo Commerce Mn holds 20,000 shares or 0% of its portfolio. Walleye Trading Ltd Limited Liability Company has 1,500 shares for 0% of their US portfolio. Cormorant Asset Mgmt Ltd Liability Company has invested 0.88% of its portfolio in Recro Pharma Inc (NASDAQ:REPH). Spark Investment Management Ltd Llc holds 38,900 shares or 0.03% of its portfolio. Moreover, Geode Cap Mgmt Limited Liability Company has 0% invested in Recro Pharma Inc (NASDAQ:REPH) for 25,775 shares. Tower Research Cap Ltd Liability Corp (Trc) has invested 0% of its portfolio in Recro Pharma Inc (NASDAQ:REPH). Bb&T accumulated 50,000 shares or 0.01% of the stock. Manufacturers Life Insurance The holds 814 shares or 0% of its portfolio. Deutsche National Bank & Trust Ag has 2,314 shares for 0% of their US portfolio. Blackrock Institutional Trust Na accumulated 49,947 shares or 0% of the stock.
Insider Transactions: Since May 31, 2016, the stock had 1 insider purchase, and 0 sales for $2.93 million net activity. Shares for $67,707 were bought by Graff Fred on Tuesday, May 31. On Tuesday, August 16 the insider Broadfin Healthcare Master Fund Ltd bought $2.93 million.
More recent Recro Pharma Inc (NASDAQ:REPH) news were published by: Marketwatch.com which released: “Recro Pharma surges 19% after positive late-stage trial for non-opioid pain …” on November 28, 2016. Also Marketwatch.com published the news titled: “/quotes/zigman/3870025/realtime” on March 10, 2014. Streetinsider.com‘s news article titled: “Form 8-K Recro Pharma, Inc. For: Nov 15” with publication date: November 15, 2016 was also an interesting one.
REPH Company Profile
Recro Pharma, Inc., incorporated on November 15, 2007, is a clinical-stage specialty pharmaceutical company. The Firm is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. The Company’s product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients. The Company’s manufacturing and development capabilities include formulation through process development, scale-up and full-scale commercial manufacturing and specialized capabilities for the development and manufacturing of controlled substances.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.